Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In ...

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat.

Verastem Oncology jumps 22% on FDA nod for Avmapki Fakzynja, the first approved KRAS-mutant LGSOC therapy, with strong early data in a pancreatic cancer study.

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In colon cancer, the second most common cause of cancer death ...

Lumakras plus Vectibix showed improved overall survival and response rates in KRAS G12C metastatic colorectal cancer, though ...

Revolution Medicines is conducting phase 3 trials for daraxonrasib, targeting active KRAS mutations, with promising results in preclinical and clinical studies. RAS(ON) therapies aim to address ...